Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CCNC | P24863 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5673590 | 0.83 | KDM4E (0.62) | APPMAPTNQO2KDM4EKMT2A | |
| SCHEMBL5673587 | 0.83 | KDM4E (0.62) | APPMAPTNQO2KDM4EKMT2A | |
| SCHEMBL5593815 | 0.78 | KDM4E (0.61) | APPMAPTKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL14619003 | 0.78 | KDM4E (0.61) | APPMAPTKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL1033828 | 0.77 | GRIN2D (0.53) | NQO2PTGS1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL11166775 | 0.77 | APP (0.54) | APPMAPTNQO2KDM4EKMT2A | |
| SCHEMBL11185942 | 0.77 | APP (0.54) | APPMAPTNQO2KDM4EKMT2A | |
| SCHEMBL294835 | 0.77 | TSHR (0.46) | MAPTKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL22231419 | 0.76 | PTGS2 (0.49) | MAPT | |
| Cyclopropane SCHEMBL11845176 | 0.76 | CNR2 (0.59) | APPMAPTNQO2KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | OXER1, OGFRL1, NR1H2 | APP 3741/4885MAPT 2044/4885NQO2 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.